Quo vadis haemapheresis. Current developments in haemapheresis.
The techniques of haemapheresis originated in the development of centrifugal devices separating cells from plasma and later on plasma from cells. Subsequently membrane filtration was developed allowing for plasma-cell separation. The unspecificity of therapeutic plasma exchange led to the development of secondary plasma separation technologies being specific, semi-selective or selective such as adsorption, filtration or precipitation. In contrast on-line differential separation of cells is still under development. Whereas erythrocytapheresis, granulocytapheresis, lymphocytapheresis and stem cell apheresis are technically advanced, monocytapheresis may need further improvement. Also, indications such as erythrocytapheresis for the treatment of polycythaemia vera or photopheresis though being clinically effective and of considerable importance for an appropriate disease control are to some extent under debate as being either too costly or without sufficient understanding of the mechanism. Other forms of cell therapy are under development. Rheohaemapheresis as the most advanced technology of extracorporeal haemorheotherapy is a rapidly developing approach contributing to the treatment of microcirculatory diseases and tissue repair. Whereas the control of a considerable number of (auto-) antibody mediated diseases is beyond discussion, the indication of apheresis therapy for immune complex mediated diseases is quite often still under debate. Detoxification for artificial liver support advanced considerably during the last years, whereas conclusions on the efficacy of septicaemia treatment are debatable indeed. LDL-apheresis initiated in 1981 as immune apheresis is well established since 24 years, other semi-selective or unspecific procedures, allowing for the elimination of LDL-cholesterol among other plasma components are also being used. Correspondingly Lp(a) apheresis is available as a specific, highly efficient elimination procedure superior to techniques which also eliminate Lp(a). Quality control systems, more economical technologies as for instance by increasing automation, influencing the over-interpretation of evidence based medicine especially in patients with rare diseases without treatment alternative, more insight into the need of controlled clinical trials or alternatively improved diagnostic procedures are among others tools ways to expand the application of haemapheresis so far applied in cardiology, dermatology, haematology, immunology, nephrology, neurology, ophthalmology, otology, paediatrics, rheumatology, surgery and transfusion medicine.
Borberg
Helmut
H
German Haemapheresis Centre, Deutsches Haemapherese Zentrum, Maarweg 165, D-50 825 Köln, Germany. hb@dhzcologne.de
D000327:Adsorption; D000328:Adult; D000368:Aged; D001781:Blood Component Removal / Q000379:methods* / Q000639:trends; D001803:Blood Transfusion / Q000379:methods; D004912:Erythrocytes / Q000166:cytology; D005260:Female; D005374:Filtration; D015316:Genetic Therapy / Q000379:methods; D006098:Granulocytes / Q000378:metabolism; D006438:Hemodilution; D006801:Humans; D006937:Hypercholesterolemia; D007154:Immune System Diseases / Q000628:therapy; D007937:Leukapheresis / Q000379:methods; D007962:Leukocytes / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism; D010956:Plasmapheresis / Q000379:methods* / Q000639:trends; D011786:Quality Control; D011788:Quality of Life; D018805:Sepsis / Q000628:therapy; D013997:Time Factors
D008077:Lipoproteins, LDL